ROIV vs. BNTX, INSM, TEVA, SMMT, GMAB, VTRS, ASND, RDY, QGEN, and MRNA
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Roivant Sciences vs. Its Competitors
Roivant Sciences (NASDAQ:ROIV) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.
Roivant Sciences currently has a consensus price target of $16.50, suggesting a potential upside of 38.83%. BioNTech has a consensus price target of $135.80, suggesting a potential upside of 22.44%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Roivant Sciences is more favorable than BioNTech.
Roivant Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
In the previous week, BioNTech had 12 more articles in the media than Roivant Sciences. MarketBeat recorded 20 mentions for BioNTech and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.55 beat BioNTech's score of 0.37 indicating that Roivant Sciences is being referred to more favorably in the media.
Roivant Sciences has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
BioNTech has a net margin of -12.20% compared to Roivant Sciences' net margin of -2,111.79%. BioNTech's return on equity of -1.84% beat Roivant Sciences' return on equity.
Summary
Roivant Sciences beats BioNTech on 9 of the 17 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ROIV) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access